Lipidomics-based safety biomarkers for lipid-lowering treatments

INIS

• safety 100%
• lipids 100%
• patients 100%
• biological markers 100%
• muscles 75%
• doses 75%
• plasma 50%
• reduction 50%
• density 25%
• risks 25%
• data 25%
• proteins 25%
• symptoms 25%
• toxicity 25%
• prediction 25%
• drugs 25%
• therapy 25%
• cholesterol 25%
• compliance 25%
• quality of life 25%
• side effects 25%
• lipoproteins 25%
• vascular diseases 25%

Keyphrases

• Lipidomics 100%
• Statins 100%
• Safety Biomarkers 100%
• Lipid-lowering Treatment 100%
• Plasma Lipidomics 40%
• Treatment Results 40%
• Lipidomic Profile 20%
• High Dose 20%
• Lipid Analysis 20%
• Clinical Practice 20%
• Good Safety 20%
• Novel Biomarkers 20%
• Highly Sensitive 20%
• Metabolic Alterations 20%
• Patient Well-being 20%
• Randomized Trial 20%
• Simvastatin 20%
• Arachidonate 5-lipoxygenase-activating Protein 20%
• Sensitive Biomarker 20%
• Cholesterol Reduction 20%
• Targeted Treatment 20%
• Low-density Lipoprotein Cholesterol (LDL-C) 20%
• Statin Drugs 20%
• Peripheral Vascular Disease 20%
• Aggressive Treatment 20%
• Improved Diagnosis 20%
• Safety Profile 20%
• Myopathy 20%
• Therapy Withdrawal 20%
• Heart Attack 20%
• Number of Patients 20%
• Statin-induced Myopathy 20%
• Patient's Will 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Biological Marker 100%
• Statin (Protein) 100%
• Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor 40%
• Myopathy 40%
• Cohort Study 20%
• Arachidonate 5 Lipoxygenase Activating Protein 20%
• Heart Infarction 20%
• Side Effect 20%
• Low Density Lipoprotein Cholesterol 20%
• Peripheral Vascular Disease 20%
• Cerebrovascular Accident 20%
• Simvastatin 20%